adobe stock.com - EtiAmmos Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118.
ADVERTISEMENT
Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118.